Muscle hypertrophy following acquired neurogenic injury: systematic review and analysis of existing literature.
Abstract
[OBJECTIVES] Neurogenic muscle hypertrophy (NMH) is a rare condition characterized by focal muscle hypertrophy caused by chronic partial nervous injury. Given its infrequency, underlying mechanisms remain poorly understood. Inspired by two clinical cases, we conducted a systematic review to gain insights into the different aspects of NMH.
[METHODS] We systematically searched online databases up until May 30, 2023, for reports of muscle hypertrophy attributed to acquired neurogenic factors. We conducted an exploratory analysis to identify commonly associated features. We also report two representative clinical cases.
[RESULTS] Our search identified 63 reports, describing 93 NMH cases, to which we added our two cases. NMH predominantly affects patients with compressive radiculopathy (68.4%), negligible muscular weakness (93.3%), and a chronic increase in muscle bulk. A striking finding in most neurophysiological studies (60.0%) is profuse spontaneous discharges, often hindering the analysis of voluntary traces. Some patients exhibited features consistent with more significant muscle damage, including higher creatine phosphokinase levels, muscle pain, and inflammatory muscle infiltration. These patients are sometimes referred to in literature as "focal myositis." Treatment encompassed corticosteroid, Botulinum Toxin A, decompressive surgery, antiepileptic medications, and nerve blocks, demonstrating varying degrees of efficacy. Botulinum Toxin A yielded the most favorable response in terms of reducing spontaneous discharges.
[INTERPRETATION] This systematic review aims to provide a clear description and categorization of this uncommon presentation of an often-overlooked neurological disorder. Though questions remain about the underlying mechanism, evidence suggests that aberrant fiber overstimulation along with increased workload that promotes focal damage may result in muscle hypertrophy. This may serve as a guide for therapeutic interventions.
[METHODS] We systematically searched online databases up until May 30, 2023, for reports of muscle hypertrophy attributed to acquired neurogenic factors. We conducted an exploratory analysis to identify commonly associated features. We also report two representative clinical cases.
[RESULTS] Our search identified 63 reports, describing 93 NMH cases, to which we added our two cases. NMH predominantly affects patients with compressive radiculopathy (68.4%), negligible muscular weakness (93.3%), and a chronic increase in muscle bulk. A striking finding in most neurophysiological studies (60.0%) is profuse spontaneous discharges, often hindering the analysis of voluntary traces. Some patients exhibited features consistent with more significant muscle damage, including higher creatine phosphokinase levels, muscle pain, and inflammatory muscle infiltration. These patients are sometimes referred to in literature as "focal myositis." Treatment encompassed corticosteroid, Botulinum Toxin A, decompressive surgery, antiepileptic medications, and nerve blocks, demonstrating varying degrees of efficacy. Botulinum Toxin A yielded the most favorable response in terms of reducing spontaneous discharges.
[INTERPRETATION] This systematic review aims to provide a clear description and categorization of this uncommon presentation of an often-overlooked neurological disorder. Though questions remain about the underlying mechanism, evidence suggests that aberrant fiber overstimulation along with increased workload that promotes focal damage may result in muscle hypertrophy. This may serve as a guide for therapeutic interventions.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 시술 | botulinum toxin
|
보툴리눔독소 주사 | dict | 2 | |
| 해부 | Muscle
|
scispacy | 1 | ||
| 해부 | nervous
|
scispacy | 1 | ||
| 해부 | muscular
|
scispacy | 1 | ||
| 해부 | focal
|
scispacy | 1 | ||
| 약물 | creatine
|
C0010286
creatine
|
scispacy | 1 | |
| 약물 | [OBJECTIVES]
|
scispacy | 1 | ||
| 약물 | creatine phosphokinase
|
scispacy | 1 | ||
| 약물 | corticosteroid
|
scispacy | 1 | ||
| 질환 | Muscle hypertrophy
|
C0236033
Muscle hypertrophy
|
scispacy | 1 | |
| 질환 | neurogenic injury
|
scispacy | 1 | ||
| 질환 | NMH
→ Neurogenic muscle hypertrophy
|
scispacy | 1 | ||
| 질환 | chronic partial nervous injury
|
scispacy | 1 | ||
| 질환 | compressive radiculopathy
|
scispacy | 1 | ||
| 질환 | muscular weakness
|
C0151786
Muscle Weakness
|
scispacy | 1 | |
| 질환 | muscle damage
|
C0410158
Muscle damage
|
scispacy | 1 | |
| 질환 | muscle pain
|
C0231528
Myalgia
|
scispacy | 1 | |
| 질환 | myositis
|
C0027121
Myositis
|
scispacy | 1 | |
| 질환 | neurological disorder
|
C0027765
nervous system disorder
|
scispacy | 1 | |
| 기타 | patients
|
scispacy | 1 | ||
| 기타 | Botulinum Toxin A
|
scispacy | 1 |
MeSH Terms
Humans; Hypertrophy; Muscle, Skeletal
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- Local therapeutic strategies for neurocutaneous dysesthesia: from capsaicin to cannabinoids.
- Comparative efficacy of intralesional therapies for keloid scars: a network meta-analysis.
- Adverse neurological events following botulinum toxin type A: A case series of post-injection seizures and paralysis.
- Decreased utilization of component separation techniques over time in complex abdominal wall reconstruction following introduction of preoperative botulinum toxin A.
- Current Perspectives on Pectoralis Minor Syndrome: A Narrative Review.